What factors drove the changes in Galapagos's revenue and profit?

What is the revenue and EPS growth rate for Galapagos year over year?

Did Galapagos beat or miss consensus estimates last quarter?

What were the key takeaways from Galapagos’s earnings call?

What guidance did Galapagos's management provide for the next earnings period?

What is Galapagos's gross profit margin?

What were the key takeaways from Galapagos's earnings call?

What does Galapagos do and what are its main business segments?

- **Strategic Shift Confirmed**: Transitioned from cell therapy to late-stage assets, with EUR 3 billion in cash for selective deals.
- **GLPG3667 Update**: Phase II success in dermatomyositis/SLE; evaluating partnerships for Phase III to minimize capital risk.
- **Cost Efficiency**: 2026 restructuring costs reduced to EUR 125-175 million (down from EUR 150-200 million), with cash flow neutrality expected by year-end.
- **Gilead Synergy**: Potential for Gilead to co-fund deals, expanding Galapagos' deal capacity beyond its cash reserves.

**【CEO Summary Section】**
- **Strategic Pivot**: Transitioned from cell therapy to a focus on late-stage clinical assets in immunology (i&amp;i) and oncology, with a pipeline of derisked opportunities.
- **Financial Flexibility**: Ended 2025 with EUR 3 billion in cash, enabling selective business development (BD) with Gilead's collaboration as a key enabler.
- **Team Restructuring**: New leadership team with expertise in BD and capital allocation; 5 new Board members added to support strategic growth.
- **Legacy Asset Update**: GLPG3667 (TYK2) Phase II results in dermatomyositis/SLE met primary endpoint; evaluating partnerships for Phase III development.

**【CFO Financial Commentary】**
- **2025 Financials**: Operating profit of EUR 295.1 million vs. 2024 loss of EUR 188.3 million, driven by EUR 1.07 billion in deferred OLCA revenue recognition.
- **Cost Management**: 2025 expenses included EUR 399.8 million in one-time costs (cell therapy wind-down, restructuring), with 2026 guidance for EUR 125-175 million in restructuring costs.
- **2026 Outlook**: Cash flow neutral to positive by year-end; EUR 2.775-2.85 billion in cash, with 72% held in USD to capitalize on higher interest rates.

**【Q&A Highlights】**
- **BD Strategy**: Prioritizes late-stage assets with clinical proof-of-concept; no deadline for transformative deals, but OLCA expiration in ~3 years adds urgency.
- **GLPG3667 Decision**: High bar for internal development; exploring partnerships to leverage external Phase III expertise and reduce capital intensity.
- **Gilead Collaboration**: Gilead may contribute to upfront payments and development costs, enhancing Galapagos' deal capacity beyond its EUR 3 billion cash pool.
- **Currency Strategy**: Increasing USD holdings to 72% (vs. 30% in 2024) to benefit from higher interest rates (4% vs. 2% in EUR).

Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript

- **Cell Therapy Wind-Down**: 365 employees impacted; works council consultations expected to conclude Q1 2026. No viable acquisition proposals received.
- **Cash Position**: EUR 3.05 billion (EUR 46/share) with EUR 77M interest income YTD. Projected cash flow neutral by end-2026.
- **Strategic Collaboration**: Gilead partnership to pursue oncology/immunology BD deals, leveraging Gilead's commercial expertise.
- **Pipeline Focus**: GLPG3667 TYK2 inhibitor Phase III data expected early 2026; next steps to be determined post-results.
- **Financial Discipline**: Cautious deal-making with focus on value creation, maintaining financial flexibility.

**【CEO Summary Section】**
- Announced intention to wind down cell therapy business after failed spin-off attempts, impacting 365 employees and closing 5 sites. Consultation with works councils expected to conclude Q1 2026.
- Formed strategic collaboration with Gilead to pursue business development (BD) opportunities, focusing on oncology and immunology assets with clinical proof-of-concept.
- Maintains EUR 3.05 billion cash balance (EUR 46/share), generating EUR 77 million interest income YTD, plus EUR 15-20 million annual Jyseleca royalties and EUR 20-35 million tax credits.
- GLPG3667 TYK2 inhibitor Phase III studies in lupus and dermatomyositis expected to report early 2026, with next steps to be determined post-data.

**【CFO Financial Commentary】**
- 9M 2025 operating loss: EUR 462.2 million (vs. EUR 125.6M 2024), driven by EUR 204.8M cell therapy impairment and EUR 135.5M restructuring costs (severance, collaboration terminations, asset impairments).
- Cash balance: EUR 3.05 billion (EUR 46/share), with 60% in USD. Anticipates end-2025 cash range: EUR 2.975-3.05 billion (excluding BD activity).
- Projected cash flow neutral to positive by end-2026, excluding BD, with EUR 100-125M 2025-2026 operating cash impact and EUR 150-200M one-time restructuring costs.

**【Q&A Highlights】**
- Cell therapy wind-down: No viable proposals received; open to offers during works council process. Anticipates EUR 100-125M annual operating cash impact 2025-2026 and EUR 150-200M one-time restructuring costs.
- BD strategy: Focus on mid-to-late-stage assets with Gilead, leveraging their commercial expertise. Financially disciplined approach, prioritizing value creation over speed.
- GLPG3667: Phase III data will guide next steps; potential partnering explored if internal development not optimal.
- Gilead collaboration: Flexible deal structures (joint acquisitions, multi-asset transactions) to maximize value for both companies.

Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript

- **CEO Transition & Focus**: Paul Stoffels retiring in 12 months; Galapagos pivoting to cell therapy, SpinCo to acquire small molecule assets.
- **GLPG5101 Milestones**: 100% CR in MCL patients; pivotal trials in 2026, potential 2028 approval. U.S. enrollment underway.
- **Financial Strength**: €500M runway to 2028; SpinCo allocated €2.45B for M&A in oncology, immunology, and virology.
- **Manufacturing Expansion**: Global DMU network targeting 250M patients, including China operations.
- **5301 Safety**: Prophylactic steroids prevent Parkinsonism; trials on track for 2026 data release.

**【CEO Summary Section】**
- **Leadership Transition**: Paul Stoffels will retire in 12 months, with Henry Gosebruch appointed as CEO of SpinCo. Thad Huston will transition to COO until August 2025.
- **Strategic Focus**: Galapagos is transitioning to a dedicated cell therapy company, with SpinCo separating to focus on small molecule assets.
- **Pipeline Progress**: GLPG5101 (CD19 CAR-T) achieved 100% complete response (CR) in MCL patients, with plans for pivotal trials in 2026 and potential approval in 2028. Enrollment in the U.S. and Europe is accelerating.
- **Manufacturing Expansion**: Decentralized Manufacturing Units (DMUs) are being expanded in the U.S., Europe, and China to support clinical and commercial supply, targeting 250 million patients globally.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: Total net revenues of €75 million, driven by collaboration and supply revenues. Operating expenses increased due to clinical expansion and restructuring costs of €111 million.
- **Cash Position**: €3.3 billion cash balance, with SpinCo allocated €2.45 billion and Galapagos retaining €500 million for cell therapy development.
- **Future Cash Flow**: Normalized annual cash burn expected to be €175-225 million, providing runway to 2028 for key clinical milestones.

**【Q&A Key Highlights】**
- **MCL Pivotal Design**: Single-arm trial followed by randomized controlled study, with data expected in 2026 and potential approval in 2028.
- **Manufacturing Compliance**: Active collaboration with FDA/EMA to ensure DMUs meet regulatory standards for commercial readiness.
- **SpinCo Strategy**: Independent entity focused on acquiring high-quality assets in oncology, immunology, and virology, with potential neurology opportunities.
- **5301 Mitigation**: Prophylactic dexamethasone use has prevented Parkinsonism recurrence in ongoing BCMA CAR-T trials.


Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript

- **Strategic Restructuring**: Split into Galapagos (cell therapy leader) and SpinCo (small molecule pipeline with Gilead). €500M runway for Galapagos to 2028.
- **CAR-T Breakthrough**: GLPG5101 achieves 100% complete response in mantle cell lymphoma with 7-day fresh cell delivery. Pivotal studies to start 2026, targeting 2028 approval.
- **Financial Strength**: €3.3B cash, €276M revenue, €74M net profit. SpinCo capitalized with €2.45B for external deals.
- **Manufacturing Edge**: Decentralized "Cocoon" system reduces cost and improves efficacy; six European sites operational, expanding to U.S. with Landmark Bio.

**【CEO Overview】**
- **2024 Strategic Milestones**: Advanced GLPG5101 (CD19 CAR-T) with FDA IND clearance and compelling Phase 1/2 data showing 100% complete response in mantle cell lymphoma. Signed partnerships with Lonza, Thermo Fisher, and Blood Centers of America to expand decentralized manufacturing. Sold Jyseleca business to Alfasigma, generating €200M savings.
- **SpinCo Separation**: Splitting into Galapagos (cell therapy-focused) and SpinCo (small molecule pipeline with Gilead collaboration). Galapagos will discontinue small molecule R&D, focusing on CAR-T and next-gen cell therapies.
- **Pipeline Prioritization**: Accelerating GLPG5101 in CLL and Richter transformation, deprioritizing GLPG5201 to streamline manufacturing. Progressing GLPG5301 (BCMA CAR-T) and initiating next-gen multi-targeted CAR-T in 2025.
- **Manufacturing Innovation**: Decentralized "vein-to-vein" in 7 days delivers fresh, fit cells, reducing costs and improving efficacy. Six European sites operational, expanding to U.S. with Landmark Bio in Boston.

**【CFO Financial Update】**
- **2024 Financials**: Total revenue €276M (€35M supply, €241M collaboration). R&D expenses €335M (+39% YoY). Net profit €74M driven by fair value gains and Jyseleca sale. Cash balance €3.3B, annual cash burn €374M (excluding M&A).
- **Post-Spin Capitalization**: Galapagos retains €500M for cell therapy development (runway to 2028). SpinCo capitalized with €2.45B to pursue external deals under OLCA with Gilead.
- **Cash Burn Guidance**: Normalized €175M-€225M annually, targeting 2028 first approval for GLPG5101.

**【Q&A Highlights】**
- **Pipeline Strategy**: Focused on GLPG5101 due to superior safety/efficacy profile; deprioritized GLPG5201 to avoid duplicative manufacturing validation. Next-gen CAR-T with multi-targeting expected in clinic by end-2025.
- **Manufacturing Scale**: U.S. expansion prioritizes high-density oncology hubs. FDA validation for pivotal studies in 2026; sites meet commercial-grade quality standards.
- **Partnership Pipeline**: Seeking collaborators for decentralized platform (e.g., Adaptimmune's uza-cel). Exploring partnerships for small molecule portfolio post-spin.
- **SpinCo Progress**: Executive team recruitment underway; regulatory filings and shareholder approval expected mid-2025.

Actual									-0.8481	-2.0861	-1.4843	-0.2315	-1.1525	-1.1439	0.2811	-0.2117	-0.2948	0.3266	-3.3206	0.3852	0.0882	0.4186		0.3876	0.0782	-0.8034	0.3023	-2.6728	-1.853	-3.5426	-0.162
Forecast									-0.5869	-0.9197	-1.35	-1.121	-1.4386	-1.7015	-1.0439	-0.6764	-0.6808	-0.8063	-0.6481	-0.9594	-0.8171	-1.1255		-0.084	-0.0741	-0.1693	-0.5485	-0.1419	-0.2283	-0.4778	-0.1265
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-44.51%	-126.82%	-9.95%	+79.35%	+19.89%	+32.77%	+126.93%	+68.70%	+56.70%	+140.51%	-412.36%	+140.15%	+110.79%	+137.19%	0.00%	+561.43%	+205.53%	-374.54%	+155.11%	-1783.58%	-711.65%	-641.44%	-28.06%

GLPG

GLPG fundamentals

GLPG Q4 2025 Earnings

Earnings Call

You can ask Aime

GLPG

GLPG fundamentals

GLPG Q4 2025 Earnings

Earnings Call

GLPG Earnings Call Summary for Q4/20258:00 AM on Feb 24, 2026

GLPG Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

GLPG Earnings Call Summary for Q2/2025 Mar 30, 2026

GLPG Earnings Call Summary for Q1/20258:00 AM on Apr 24, 2025

GLPG Earnings Call Summary for Q4/20248:00 AM on Feb 13, 2025

You can ask Aime